Wall Street Analysts Believe Travere Could Rally 42.56 percent Heres is How to Trade
TVTX Stock | USD 19.00 0.08 0.42% |
Slightly above 79 percent of Travere Therapeutics' investors are selling. The analysis of the overall investor sentiment regarding Travere Therapeutics suggests that a fairly large number of traders are terrified. Travere Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Travere Therapeutics' earnings reports, geopolitical events, and overall market trends.
Travere |
The average of price targets set by Wall Street analysts indicates a potential upside of 42.6 percent in Travere . While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read at zacks.com
Travere Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Travere Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Travere Therapeutics Maximum Pain Price Across January 17th 2025 Option Contracts
Travere Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Travere Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Travere Therapeutics' options.
Travere Therapeutics Fundamental Analysis
We analyze Travere Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Travere Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Travere Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Travere Therapeutics is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Travere Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Travere Therapeutics stock to make a market-neutral strategy. Peer analysis of Travere Therapeutics could also be used in its relative valuation, which is a method of valuing Travere Therapeutics by comparing valuation metrics with similar companies.
Peers
Travere Therapeutics Related Equities
RVMD | Revolution Medicines | 0.20 | ||||
MGTX | MeiraGTx Holdings | 0.16 | ||||
GPCR | Structure Therapeutics | 0.52 | ||||
AKRO | Akero Therapeutics | 1.69 | ||||
COGT | Cogent Biosciences | 1.70 | ||||
PTGX | Protagonist Therapeutics | 2.16 | ||||
IDYA | Ideaya Biosciences | 2.24 | ||||
NUVL | Nuvalent | 2.33 | ||||
CYTK | Cytokinetics | 2.35 | ||||
LEGN | Legend Biotech | 2.35 | ||||
RNA | Avidity Biosciences | 2.79 | ||||
ANAB | AnaptysBio | 3.17 | ||||
STOK | Stoke Therapeutics | 3.76 | ||||
APLS | Apellis Pharmaceuticals | 4.71 | ||||
KROS | Keros Therapeutics | 6.00 | ||||
PCVX | Vaxcyte | 7.14 | ||||
VTYX | Ventyx Biosciences | 10.71 |
Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.